$3.18
+0.13
(+4.26%)▲
Revenue is down for the last 2 quarters, 2.97M → 1.72M (in $), with an average decrease of 42.2% per quarter
Netprofit is up for the last 2 quarters, -100.18M → -31.26M (in $), with an average increase of 220.4% per quarter
In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 107.9%
5.03%
Downside
Day's Volatility :5.63%
Upside
0.63%
11.64%
Downside
52 Weeks Volatility :79.93%
Upside
77.29%
Period | CENTURY THERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -32.37% | -0.3% | -6.7% |
6 Months | -70.95% | -8.8% | -6.2% |
1 Year | -64.9% | -4.2% | -5.1% |
3 Years | -88.95% | 23.0% | 26.9% |
Market Capitalization | 180.5M |
Book Value | $4.69 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.01 |
Wall Street Target Price | 18.3 |
Profit Margin | 0.0% |
Operating Margin TTM | -2192.05% |
Return On Assets TTM | -15.96% |
Return On Equity TTM | -37.56% |
Revenue TTM | 5.9M |
Revenue Per Share TTM | 0.1 |
Quarterly Revenue Growth YOY | 62.6% |
Gross Profit TTM | 5.2M |
EBITDA | -118.3M |
Diluted Eps TTM | -2.01 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.09 |
EPS Estimate Next Year | -2.12 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 475.47%
Sell
Neutral
Buy
CENTURY THERAPEUTICS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() CENTURY THERAPEUTICS INC | -4.98% | -70.95% | -64.9% | -88.95% | -88.95% |
![]() Moderna, Inc. | -3.38% | -26.73% | -11.31% | 107.29% | 592.96% |
![]() Regeneron Pharmaceuticals, Inc. | -9.68% | -3.07% | 9.61% | 21.54% | 142.61% |
![]() Seagen, Inc. | -2.59% | 59.82% | 42.99% | 22.0% | 220.73% |
![]() Vertex Pharmaceuticals Incorporated | -5.71% | 2.81% | 21.09% | 13.49% | 111.23% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() CENTURY THERAPEUTICS INC | 45.5 | NA | NA | -2.09 | -0.38 | -0.16 | 0.0 | 4.69 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() CENTURY THERAPEUTICS INC | Buy | $180.5M | -88.95% | 45.5 | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 592.96% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 142.61% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 220.73% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 111.23% | 26.53 | 35.4% |
FMR Inc
Casdin Capital, LLC
BlackRock Inc
Dafna Capital Management LLC
Avidity Partners Management LP
Federated Hermes Inc
Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.
Organization | CENTURY THERAPEUTICS INC |
Employees | 163 |
CEO | Dr. Osvaldo Flores Ph.D. |
Industry | Non-Energy Minerals |
First Majestic Silver Corp
$5.77
+1.23%
ONYX ACQUISITION CO. I
$11.00
+0.0%
Diversified Healthcare Trust
$1.36
+7.94%
ALTC ACQUISITION CORP-CL A
$10.70
-0.05%
iShares Morningstar Value ETF
$62.95
-0.57%
Nationwide Nasdaq-100 Risk-Managed Income ETF
$20.49
-0.05%
ENFUSION INC
$7.96
+2.98%
WisdomTree Trust - WisdomTree International Quality Dividend Growth Fund
$33.22
-0.79%
GIGACLOUD TECHNOLOGY INC
$6.75
-0.15%